{
  "submitter" : "Reach",
  "model_relation" : "extension",
  "extracted_information" : {
    "interaction_type" : "increases_activity",
    "negative_information" : false,
    "participant_b" : {
      "in_model" : true,
      "identifier" : "uaz:UAZ00402",
      "entity_text" : "angiotensin-converting enzyme inhibitors",
      "entity_type" : "simple_chemical"
    },
    "participant_a" : {
      "in_model" : true,
      "identifier" : "pubchem:2336",
      "entity_text" : "BP",
      "entity_type" : "simple_chemical"
    },
    "hypothesis_information" : false
  },
  "verbose_text" : "Several large meta-analyses, using data from randomized clinical trials (RCTs) or observational studies, demonstrated that BP lowering significantly reduces vascular risk across various baseline BP levels and comorbidities.5, 7, 8, 9, 10 Pharmacological options for initiation and maintenance of antihypertensive therapy include diuretics, beta-blockers (BB), calcium channel blockers (CCB), angiotensin converting enzyme inhibitors (ACEi), and angiotensin receptor blockers (ARB).",
  "reading_complete" : "2020-08-05T22:02:33Z",
  "reader_type" : "machine",
  "reading_started" : "2020-08-05T22:01:09Z",
  "trigger" : "reduces",
  "evidence" : [ "BP lowering significantly reduces vascular risk across various baseline BP levels and comorbidities.5, 7, 8, 9, 10 Pharmacological options for initiation and maintenance of antihypertensive therapy include diuretics, beta-blockers (BB), calcium channel blockers (CCB), angiotensin-converting enzyme inhibitors" ],
  "pmc_id" : "6916605",
  "score" : 0
}